Sumitomo Pharma Co., Ltd. (DNPUF)

Sumitomo Pharma Balance Sheet

Financials in millions JPY. Fiscal year is April - March.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2025	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Cash & Equivalents	38,490	23,116	29,047	143,478	202,984	193,698
Cash & Short-Term Investments	38,490	23,116	29,047	143,478	202,984	193,698
Cash Growth	-61.15%	-20.42%	-79.75%	-29.32%	4.79%	90.44%
Accounts Receivable	124,548	74,840	81,023	95,908	151,407	135,866
Other Receivables	2,715	2,886	16,216	2,722	93	194
Receivables	127,263	77,726	97,239	98,630	151,500	136,060
Inventory	82,755	94,222	115,350	94,405	99,021	92,215
Other Current Assets	22,600	58,104	27,933	45,347	46,016	37,822
Total Current Assets	271,108	253,168	269,569	381,860	499,521	459,795
Property, Plant & Equipment	44,939	46,648	57,895	58,909	64,091	64,966
Long-Term Investments	31,951	72,339	182,368	144,399	127,909	203,277
Goodwill	196,457	197,406	199,783	209,415	195,144	176,492
Other Intangible Assets	166,510	172,509	195,652	329,314	398,692	383,406
Long-Term Deferred Tax Assets	464	534	2,239	10,845	22,650	20,191
Other Long-Term Assets	66,975	-	-	-	-	-
Total Assets	778,404	742,604	907,506	1,134,742	1,308,007	1,308,127
Accounts Payable	42,046	38,544	67,720	52,141	46,183	64,638
Short-Term Debt	-	42,440	174,588	90,588	5,025	5,000
Current Portion of Long-Term Debt	4,000	4,000	110,929	-	20,060	4,960
Current Portion of Leases	-	3,354	3,781	4,660	5,463	5,900
Current Income Taxes Payable	4,388	1,577	1,348	24,053	7,583	24,511
Other Current Liabilities	148,595	147,224	157,108	199,446	194,059	173,138
Total Current Liabilities	199,029	237,139	515,474	370,888	278,373	278,147
Long-Term Debt	258,850	258,982	133,367	244,128	243,963	263,859
Long-Term Leases	-	5,470	5,199	6,996	10,033	10,961
Pension & Post-Retirement Benefits	6,297	6,534	11,150	5,008	11,461	15,069
Long-Term Deferred Tax Liabilities	14,199	26,550	38,211	36,505	26,550	28,424
Other Long-Term Liabilities	34,441	38,450	47,969	64,435	64,058	63,489
Total Liabilities	512,816	573,125	751,370	727,960	634,438	659,949
Common Stock	22,400	22,400	22,400	22,400	22,400	22,400
Additional Paid-In Capital	-	-	-	-	16,725	15,855
Retained Earnings	147,516	46,784	-22,665	280,999	514,210	508,677
Treasury Stock	-682	-682	-682	-682	-681	-679
Comprehensive Income & Other	96,354	100,977	157,010	104,032	55,234	34,317
Total Common Equity	265,588	169,479	156,063	406,749	607,888	580,570
Minority Interest	-	-	73	33	65,681	67,608
Shareholders' Equity	265,588	169,479	156,136	406,782	673,569	648,178
Total Liabilities & Equity	778,404	742,604	907,506	1,134,742	1,308,007	1,308,127
Total Debt	262,850	314,246	427,864	346,372	284,544	290,680
Net Cash (Debt)	-224,360	-291,130	-398,817	-202,894	-81,560	-96,982
Net Cash Per Share	-564.73	-732.79	-1003.84	-510.69	-205.29	-244.11
Filing Date Shares Outstanding	397.29	397.29	397.29	397.29	397.29	397.29
Total Common Shares Outstanding	397.29	397.29	397.29	397.29	397.29	397.29
Working Capital	72,079	16,029	-245,905	10,972	221,148	181,648
Book Value Per Share	668.50	426.59	392.82	1023.80	1530.08	1461.31
Tangible Book Value	-97,379	-200,436	-239,372	-131,980	14,052	20,672
Tangible Book Value Per Share	-245.11	-504.51	-602.51	-332.20	35.37	52.03

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.